The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens
Open accessAbstract
Establishing a cancer screening biomarker's intended performance requires “phase III” specimens obtained in asymptomatic individuals before clinical diagnosis rather than “phase II” specimens obtained from symptomatic individuals at diagnosis. We used specimens from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial to evaluate ovarian cancer biomarkers previously assessed in phase II sets. Phase II specimens from 180 ovarian cancer cases and 660 benign disease or general population controls were assembled from four Early Detection Research Network or Ovarian Cancer Specialized Program of Research Excellence sites and used to rank 49 biomarkers. Thirty-five markers, including 6 additional markers from a fifth site, were then evaluated in PLCO proximate specimens from 118 women with ovarian cancer and 474 matched controls. Top markers in phase II specimens included CA125, HE4, transthyretin, CA15.3, and CA72.4 with sensitivity at 95% specificity ranging from 0.73 to 0.40. Except for transthyretin, these markers had similar or better sensitivity when moving to phase III specimens that had been drawn within 6 months of the clinical diagnosis. Performance of all markers declined in phase III specimens more remote than 6 months from diagnosis. Despite many promising new markers for ovarian cancer, CA125 remains the single-best biomarker in the phase II and phase III specimens tested in this study. Cancer Prev Res; 4(3); 365–74. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use of proteomic patterns in serum to identify ovarian cancer
Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J., Fusaro, V. A., Steinberg, S. M., Mills, G. B., Simone, C., Fishman, D. A., Kohn, E. C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07746-2 · Cited by 3,236
Phases of Biomarker Development for Early Detection of Cancer
Pepe, M. S., Etzioni, R., Feng, Z., Potter, J. D., Thompson, M. L., Thornquist, M., Winget, M., & Yasui, Y. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1054 · Cited by 1,686
Self-citationZhang, Z., Bast, R. C., Yu, Y., Li, J., Sokoll, L. J., Rai, A. J., Rosenzweig, J. M., Cameron, B., Wang, Y. Y., Meng, X.-Y., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0746 · Cited by 934
Self-citationMenon, U., Gentry-Maharaj, A., Hallett, R., Ryan, A., Burnell, M., Sharma, A., Lewis, S., Davies, S., Philpott, S., Lopes, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70026-9 · Cited by 829
Self-citationScreening for ovarian cancer: a pilot randomised controlled trial
Jacobs, I. J., Skates, S. J., MacDonald, N., Menon, U., Rosenthal, A. N., Davies, A. P., Woolas, R., Jeyarajah, A. R., Sibley, K., Lowe, D. G., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10261-1 · Cited by 560
Self-citationGohagan, J. K., Prorok, P. C., Hayes, R. B., & Kramer, B.-S. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00097-0 · Cited by 544
Serum protein markers for early detection of ovarian cancer
Mor, G., Visintin, I., Lai, Y., Zhao, H., Schwartz, P., Rutherford, T., Yue, L., Bray-Ward, P., & Ward, D. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502178102 · Cited by 482
Self-citationClarke-Pearson, D. L. (2009) · New England Journal of Medicine · doi:10.1056/nejmcp0901926 · Cited by 400
Multiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian Cancer
Gorelik, E., Landsittel, D. P., Marrangoni, A. M., Modugno, F., Velikokhatnaya, L., Winans, M. T., Bigbee, W. L., Herberman, R. B., & Lokshin, A. E. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0404 · Cited by 264
Self-citationResults From Four Rounds of Ovarian Cancer Screening in a Randomized Trial
Partridge, E., Kreimer, A. R., Greenlee, R. T., Williams, C., Xu, J.-L., Church, T. R., Kessel, B., Johnson, C. C., Weissfeld, J. L., Isaacs, C., et al. (2009) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31819cda77 · Cited by 258
Cited by
Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.
Kinde, I., Bettegowda, C., Wang, Y., Wu, J., Agrawal, N., Shih, I.-M., Kurman, R., Dao, F., Levine, D. A., Giuntoli, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004952 · Cited by 327
Ovarian Cancer: Etiology, Risk Factors, and Epidemiology
HUNN, J., & RODRIGUEZ, G. C. (2012) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e31824b4611 · Cited by 324
Trabert, B., Ness, R. B., Lo-Ciganic, W.-H., Murphy, M. A., Goode, E. L., Poole, E. M., Brinton, L. A., Webb, P. M., Nagle, C. M., Jordan, S. J., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt431 · Cited by 243
Self-citationKim, M., Chen, C., Wang, P., Mulvey, J. J., Yang, Y., Wun, C., Antman-Passig, M., Luo, H.-B., Cho, S., Long-Roche, K., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00860-y · Cited by 214
Plasma MicroRNAs as Novel Biomarkers for Endometriosis and Endometriosis-Associated Ovarian Cancer
Suryawanshi, S., Vlad, A. M., Lin, H.-M., Mantia-Smaldone, G., Laskey, R., Lee, M., Lin, Y., Donnellan, N., Klein-Patel, M., Lee, T., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2726 · Cited by 197
Metadata
- Authors
- Cramer, D. W., Bast, R. C., Berg, C. D., Diamandis, E. P., Godwin, A. K., Hartge, P., Lokshin, A. E., Lu, K. H., McIntosh, M. W., Mor, G., Patriotis, C., Pinsky, P. F., Thornquist, M. D., Scholler, N., Skates, S. J., Sluss, P. M., Srivastava, S., Ward, D. C., Zhang, Z., Zhu, C. S., & Urban, N.
- Venue
- Cancer Prevention Research
- Published
- 2011-03-01
- Volume
- 4
- Issue
- 3
- Pages
- 365-374
- ISSN
- 1940-6207 (ISSN-L)
- 1940-6215
- OpenAlex
- W2155587446
- Cited by
- 300
- References
- 18
- FWCI
- 38.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens. https://app.cochat.ai/papers/10.1158/1940-6207.capr-10-0195
- The paper
- Cramer, D. W., Bast, R. C., Berg, C. D., Diamandis, E. P., Godwin, A. K., Hartge, P., Lokshin, A. E., Lu, K. H., McIntosh, M. W., Mor, G., Patriotis, C., Pinsky, P. F., Thornquist, M. D., Scholler, N., Skates, S. J., Sluss, P. M., Srivastava, S., Ward, D. C., Zhang, Z., . . . Urban, N. (2011). Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens. Cancer Prevention Research. https://doi.org/10.1158/1940-6207.capr-10-0195
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.